Amgen has reported that the Phase III clinical trial of its ABP 654 in adults with moderate to severe plaque psoriasis met the primary efficacy endpoint. 

The company is developing ABP 654 as a biosimilar candidate to Stelara (ustekinumab).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

An approved human interleukin-12 and interleukin-23 antagonist, Stelara is intended to treat moderate to severe plaque psoriasis in adults and paediatric patients aged six years or above who have received phototherapy or systemic therapy, as well as active psoriatic arthritis in adults. 

It is also indicated to treat moderately to severely active Crohn’s disease and moderately to severely active ulcerative colitis in adults. 

ABP 654 has the same dosage strength, pharmaceutical form, administration route and dosing regimen as ustekinumab, which is licensed in the US and approved in the European Union (EU).

The multicentre, randomised, double-blinded, comparative trial assessed the safety and efficacy of ABP 654 versus Stelara in adult moderate to severe plaque psoriasis patients. 

The trial enrolled 563 subjects who were categorised to receive either ABP 654 or ustekinumab.

According to the initial data, the trial met the primary efficacy endpoint, showing no clinically meaningful differences between ABP 654 and Stelara.

The primary assessment analysed the percentage improvement of psoriasis area severity index (PASI) from baseline to week 12, which demonstrated a mean difference of 0.14 between ABP 654 and Stelara and was found to be within the prespecified margins. 

Furthermore, the safety profile of ABP 654 was in line with Stelara.

Amgen Research and Development executive vice-president David Reese said: “Amgen remains committed to providing patients who live with inflammatory diseases access to high-quality biosimilar medicines. 

“We look forward to continuing to expand our inflammation portfolio to offer patients a variety of treatment options.”

A serious, chronic inflammatory ailment, psoriasis leads to raised, red, scaly patches on the skin.

The company currently has 11 biosimilars in its portfolio, with five approved by the US Food and Drug Administration (FDA) and three approved for use in the EU.

The latest development comes after Amgen reported long-term efficacy and safety data from the Phase I/II CodeBreaK 100 trial of Lumakras (sotorasib) in KRAS G12C-mutated advanced non-small cell lung cancer patients.